Research Paper Volume 13, Issue 18 pp 22286—22297

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

ASXL1 silencing sensitized ACC cells to etoposide, doxorubicin, cisplatin and mitotane (EDP-M) regimen. Xenograft murine models consisting of 8 male BALB/c nude mice per group undergoing EDP-M regimen () or vehicle control (Veh) with subcutaneous implanted with (A) NCI-H295R cells with or without ASXL1 silencing under left flank with tumor growth monitored over 60-day period and tumor size of 3 as endpoint, and (B) Kaplan-Meier curves of survival of mice; and with (C) SW-13 cells with or without ASXL1 silencing under left flank with tumor growth monitored over 60-day period and tumor size of 3 as endpoint, and (D) Kaplan-Meier curves of survival of mice; (E) Quantitative PCR showing expression of ASXL3 in ACC cell lines treated with EDP regimen; (F) Representative image of immunohistochemical staining of ASXL1 and ASXL3 in harvested tumors from xenograft models (scale bar = 100 μm, *P

Figure 5. ASXL1 silencing sensitized ACC cells to etoposide, doxorubicin, cisplatin and mitotane (EDP-M) regimen. Xenograft murine models consisting of 8 male BALB/c nude mice per group undergoing EDP-M regimen () or vehicle control (Veh) with subcutaneous implanted with (A) NCI-H295R cells with or without ASXL1 silencing under left flank with tumor growth monitored over 60-day period and tumor size of < 2000 mm3 as endpoint, and (B) Kaplan-Meier curves of survival of mice; and with (C) SW-13 cells with or without ASXL1 silencing under left flank with tumor growth monitored over 60-day period and tumor size of < 2000 mm3 as endpoint, and (D) Kaplan-Meier curves of survival of mice; (E) Quantitative PCR showing expression of ASXL3 in ACC cell lines treated with EDP regimen; (F) Representative image of immunohistochemical staining of ASXL1 and ASXL3 in harvested tumors from xenograft models (scale bar = 100 μm, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).